In this article, we will look at the Top 15 Low Volatility Healthcare Stocks to Buy Now.
On July 21, Dr. Warris Bokhari, Claimable CEO and co-founder, appeared on CNBC’s ‘Squawk Box’ to talk about the use of AI to appeal health care insurance denials, and more.
A majority of Americans have experienced the frustration of getting a healthcare insurance denial, often times finding no solution despite emails with service providers and phone calls with carriers. Dr. Bokhari runs a platform that can change that, as it uses AI to appeal denials for care to treat around 70 autoimmune conditions, including Crohn’s disease and others.
READ ALSO: 10 Best Strong Buy Healthcare Stocks to Buy Now and 11 Best Shipping and Container Stocks to Invest in Now.
Patients fill out a form, after which AI handles the next processes, scanning healthcare plans and relevant state and federal laws.
Dr. Bokhari stated that the platform’s inception came from a decade long observation of one of America’s unique problems, as there are around 850 million denials every year, and only around 1% of them are ever appealed. These statistics translate to around 70-90 million Americans every year who struggle with insurance issues such as denials.
Launched on October 2, 2024, in the US only, the platform helps patients appeal care denials for 70 autoimmune diseases, using AI to generate appeal letters based on healthcare plans.
With these trends in view, lets look at the 15 low volatility healthcare stocks to buy now.
A healthcare professional wearing a lab coat, holding a vial of medication.
Our Methodology
We used Finviz to compile a list of healthcare stocks with a beta below 1 and selected the top 15 with the highest number of hedge fund holders as of Q1 2025, sourcing the hedge fund sentiment data from Insider Monkey’s database. The list is sorted in ascending order of hedge fund sentiment.
Note: All data was recorded on July 24.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
Top 15 Low Volatility Healthcare Stocks to Buy Now
15. Novo Nordisk A/S (NYSE:NVO)
Beta: 0.22
Number of Hedge Fund Holders: 60
Novo Nordisk A/S (NYSE:NVO) is one of the top low volatility healthcare stocks to buy now. In a report released on July 17, David Evans from Kepler Capital maintained a Buy rating on Novo Nordisk A/S (NYSE:NVO) with a price target of DKK630.00.
Novo Nordisk A/S (NYSE:NVO) reported a 22% growth in operating profit in Danish kroner and 20% at constant exchange rates (CER) to DKK 38.8 billion in the first three months of 2025.
Sales in US Operations rose by 20% in Danish kroner and 17% at CER, while sales in International Operations grew by 18% in Danish kroner and 19% at CER in the same period.
Novo Nordisk A/S (NYSE:NVO) also experienced a 21% growth in Danish kroner in sales within Diabetes and Obesity care, primarily attributed to the Obesity care growth of 67% in Danish kroner to DKK 18.4 billion and GLP-1 diabetes sales growth of 13% in Danish kroner.
Novo Nordisk A/S (NYSE:NVO) is a global healthcare company specializing in diabetes care. It develops, discovers, manufactures, and markets pharmaceutical products.
Its operations are divided into two business segments: biopharmaceuticals and diabetes and obesity care. The latter segment covers GLP-1, insulin, and other protein-related products.
14. Stryker Corporation (NYSE:SYK)
Beta: 0.92
Number of Hedge Fund Holders: 61
Stryker Corporation (NYSE:SYK) is one of the top low volatility healthcare stocks to buy now. In a report released on July 20, Josh Jennings from TD Cowen maintained a Buy rating on Stryker Corporation (NYSE:SYK) with a price target of $435.00.
The analyst based the optimistic rating on the company’s strong performance in recent quarters and the anticipation of continued momentum.
Jennings stated that Stryker Corporation (NYSE:SYK) has consistently experienced robust growth, reporting a notable 10% organic growth in Q1, which translates to around 11.1% when adjusted for a selling day headwind.
He further stated that Stryker Corporation (NYSE:SYK) is positioned against one of its easier comparisons from 2024 despite an expected slowdown in growth to 8.8% for Q2.
According to Jennings, the company has historically achieved double-digit growth even in the backdrop of challenging benchmarks, suggesting that the present market estimates are well-founded.
Stryker Corporation (NYSE:SYK) is a medical technology company that offers products and services in Neurotechnology, Medical and Surgical, and Orthopedics and Spine. It operates through the MedSurg and Neurotechnology and the Orthopedics and Spine segments.
The company’s medical devices and products include surgical navigation systems, surgical equipment, emergency medical equipment, endoscopic and communications systems, neurosurgical and neurovascular devices, Mako Robotic-Arm Assisted technology, and several other products. Stryker Corporation (NYSE:SYK) holds around 13,000 global patents to shield its products from replication.
